Divestment of a Pharmaceutical Manufacturing Facility in Barberà del Vallès, Spain
PharmaVentures advises Novartis on the sale of its manufacturing facility in Barberà del Vallès to Siegfried Holding AG.
Oxford, UK, 5th October 2020
PharmaVentures Ltd (“PharmaVentures”) is pleased to announce that it was the corporate finance advisor to Novartis on the divestment of its manufacturing facility in Barberà del Vallès, Spain, to Siegfried Holding AG, a global contract development and manufacturing organisation (CDMO).
PharmaVentures is a premier transaction advisory firm; a world leader in partnering, pharma M&A deals and strategic alliances.
An unrivalled bank of specialist experience, deal analytics and network of contacts among innovators and large pharma makes PharmaVentures uniquely placed to support healthcare businesses in all aspects of deal-making and strategic planning. PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest.
PharmaVentures Capital Ltd is a wholly owned subsidiary of PharmaVentures Ltd. All regulated activities are delivered through PharmaVentures Capital Ltd, which is authorised and regulated by the Financial Conduct Authority (741356). PharmaVentures Capital Ltd undertakes regulated activities for and on behalf of professional clients only as defined in the FCA handbook COBS 3.5.